COMEM NATURAL JSC: GLP-1 import refusal records

Has FDA refused imports of GLP-1 products from COMEM NATURAL JSC?

Yes. FDA’s import refusal records list 3 refused shipment lines declared as made by COMEM NATURAL JSC (Vietnam) whose FDA product code names retatrutide, on Sep 24, 2026. None of them carries a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.

Country
Vietnam
City in FDA records
Ha Noi
FEI numbers on the lines
3044410908
Refused lines
3
Lines with an Import Alert 66-80 API or powder code
0
Drugs named in the product codes
Retatrutide
Refusal dates
Sep 24, 2026

The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.

Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether COMEM NATURAL JSC is on it.

Refused shipment lines

FDA refusal chargesShipment ID
Sep 24, 2026Vietnam61PDZ78 RETATRUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80708NOREG A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug and appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.
708LIST A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears to not be included in a list required by section 510(j).

708LBLFR A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears in a package form to not bear a label containing the name and place of business of the manufacturer, packer, or distributor.
1FX-2060079-8/20002/1D
Sep 24, 2026Vietnam61PDZ78 RETATRUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80708NOREG A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug and appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.
708LIST A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears to not be included in a list required by section 510(j).

708LBLFR A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears in a package form to not bear a label containing the name and place of business of the manufacturer, packer, or distributor.
1FX-2060079-8/20002/1H
Sep 24, 2026Vietnam61PDZ78 RETATRUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80708NOREG A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug and appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.
708LIST A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears to not be included in a list required by section 510(j).

708LBLFR A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears in a package form to not bear a label containing the name and place of business of the manufacturer, packer, or distributor.
1FX-2060079-8/20002/1I

FDA refusal charges on these lines

A line can carry several charges. Text is FDA’s charge statement, verbatim.

708NOREG A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug and appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.3
708LIST A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears to not be included in a list required by section 510(j).3
708LBLFR A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears in a package form to not bear a label containing the name and place of business of the manufacturer, packer, or distributor.3

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.

3 lines from FDA files read Nov 15, 2026.